单倍体HSCT对比强化化疗用于极高危Ph阴性儿童B-ALL缓解后治疗的生存优势
该回顾性研究纳入104例首次完全缓解的极高危Ph阴性儿童B细胞急性淋巴细胞白血病患者,其中42例接受未处理单倍体造血干细胞移植,62例继续化疗。MRD持续阳性或由阴转阳及化疗是长期生存差和复发率高的独立危险因素,单倍体移植可能优于强化化疗。
要点
- 极高危Ph阴性儿童B-ALL首次缓解后,单倍体HSCT可能较强化化疗获得更好生存。
- MRD持续阳性或由阴转阳是长期生存差和复发率高的独立危险因素。
- 在MRD持续阳性或阴转阳患者中,两组OS、DFS和CIR差异显著。
核心结论
- 单倍体HSCT可作为极高危Ph阴性儿童B-ALL首次完全缓解后的缓解后治疗选择,尤其适用于MRD持续阳性或由阴转阳者,可能较强化化疗获得更好生存。
研究设计与样本
- 回顾性研究,纳入104例首次完全缓解的极高危Ph阴性儿童B-ALL患者,42例接受未处理单倍体HSCT(A组),62例接受持续化疗(B组)。
主要发现
- MRD持续阳性或由阴转阳及化疗是长期生存差和累积复发率高的独立危险因素。
- 在MRD持续阳性或阴转阳患者中,两组总生存、无病生存和累积复发率差异显著。
关键数值与推荐
- 极高危Ph阴性儿童B-ALL首次完全缓解后,单倍体HSCT可能为缓解后治疗选项,尤其MRD持续阳性或由阴转阳者。
临床怎么用
- 对极高危Ph阴性儿童B-ALL首次完全缓解患者,尤其MRD持续阳性或由阴转阳者,可考虑未处理单倍体HSCT作为缓解后治疗。
局限性
- 本研究为回顾性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We explored the prognostic factors for children with very high-risk (VHR) Philadelphia chromosome (Ph) negative B-cell acute lymphoblastic leukaemia (B-ALL) and compared the therapeutic effects of intensive chemotherapy and unmanipulated haploidentical haematopoietic stem cell transplantation (haplo-HSCT) as post-remission treatment in these patients undergoing first complete remission (CR1). A total of 104 paediatric patients with VHR B-ALL in CR1 were retrospectively enrolled in this study, including 42 receiving unmanipulated haplo-HSCT (Group A) and 62 receiving ongoing chemotherapy (Group B). Estimated 3-year overall survival (OS), disease-free survival (DFS) and cumulative incidence of relapse (CIR) at 36·2 months median follow-up were 69·5 ± 4·7%, 63·5 ± 4·8% and 32·4 ± 4·7%, respectively. Maintenance of persistent positive or conversion from negative to positive of measurable residual disease (MRD) and chemotherapy were independent risk factors associated with inferior long-term survival and higher CIR. OS, DFS, and CIR differed significantly between the groups in patients with persistent positive or negative-to-positive MRD. Haplo-HSCT may be an option for children with VHR Ph-negative B-ALL in CR1, especially for patients with persistent positive or negative-to-positive MRD, and could achieve better survival than intensive chemotherapy as post-remission treatment.
引用
- Xue YJ, Suo P, Huang XJ, et al. Superior survival of unmanipulated haploidentical haematopoietic stem cell transplantation compared with intensive chemotherapy as post-remission treatment for children with very high-risk philadelphia chromosome negative B-cell acute lymphoblastic leukaemia in first complete remission. Br J Haematol. 2019. PMID: 31725190. doi:10.1111/bjh.16226
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。